Skip to main content
SpringerLink
Log in

Cognition in schizophrenia

  • Published:
Current Psychiatry Reports Aims and scope Submit manuscript

Abstract

Cognitive dysfunction has been described as a hallmark feature of schizophrenia since the first descriptions of the illness. Kraepelin described a number of features of the disorder that he thought reflected impairments in cognition and attention. He also speculated that cognitive impairments were mediated by neurobiologic dysfunction, specifically impairments in the functions of the frontal lobe. Since Kraepelin’s time, there have been many changes in the general conceptions of schizophrenia, including ideas regarding the status and importance of cognitive impairment in the illness. Due to increased sophistication of neuropsychologic assessment and neuroimaging techniques, cognitive impairment has again has risen to the forefront of importance in terms of theories regarding the etiology and treatment of schizophrenia.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Kraepelin E: Dementia Praecox and Paraphrenia. Edinburgh: Livingstone; 1919.

    Google Scholar 

  2. Palmer BW, Heaton RK, Paulsen JS, et al.: Is it possible to be schizophrenic yet neuropsychologically normal? Neuropsychology 1997, 11:437–446.

    Article  PubMed  CAS  Google Scholar 

  3. Hyde TM, Nawroz S, Goldberg TE, et al.: Is there cognitive decline in schizophrenia? A cross-sectional study. Br J Psychiatry 1994, 164:494–500.

    Article  PubMed  CAS  Google Scholar 

  4. Rund BR: A review of longitudinal studies of cognitive functions in schizophrenia patients. Schizophr Bull 1998, 24:425–435.

    PubMed  CAS  Google Scholar 

  5. Harvey PD, Silverman JM, Mohs RC, et al.: Cognitive decline in late-life schizophrenia: a longitudinal study of geriatric chronically hospitalized patients. Biol Psychiatry 1999, 45:32–40.

    Article  PubMed  CAS  Google Scholar 

  6. Harvey PD, Parrella M, White L, et al.: The convergence of cognitive and adaptive decline in late-life schizophrenia. Schizophr Res 1999, 35:77–84.

    Article  PubMed  CAS  Google Scholar 

  7. Amminger GP, Schlogelhofer M, Lehner T, et al.: Premorbid performance IQ deficit in schizophrenia. Acta Psychiatr Scand 2000, 102:414–422.

    Article  PubMed  CAS  Google Scholar 

  8. Cannon TD, Bearden CE, Hollister JM, et al.: Childhood cognitive functioning in schizophrenia patients and their unaffected siblings: a prospective cohort study. Schizophr Bull 2000, 26:379–393. This study assesses the course of and the degree to which cognitive deficits in childhood predict schizophrenia. The results suggest that premorbid cognitive dysfunction of schizophrenia is a relatively stable indicator of vulnerability.

    PubMed  CAS  Google Scholar 

  9. Bilder RM, Goldman RS, Robinson D: Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. Am J Psychiatry 2000, 157:549–559.

    Article  PubMed  CAS  Google Scholar 

  10. Riley EM, McGovern D, Mockler D, et al.: Neuropsychological functioning in first-episode psychosis: evidence of specific deficits. Schizophr Res 2000, 43:47–55.

    Article  PubMed  CAS  Google Scholar 

  11. Mojtabai R, Bromet EJ, Harvey PD, et al.: Neuropsychological differences between first-admission schizophrenia and psychotic affective disorders. Am J Psychiatry 2000, 157:1453–1460.

    Article  PubMed  CAS  Google Scholar 

  12. Weickert TW, Goldberg TE, Gold JM, et al.: Cognitive impairments in patients with schizophrenia displaying preserved and compromised intellect. Arch Gen Psychiatry 2000, 57:907–913. Given the inconsistencies in the literature, this work helps to elucidate the course and pattern of neurocognitive deficits in schizophrenia. The results suggested a modal decline in IQ from estimated premorbid levels. However, the results also suggest that intellectual decline is not a universal characteristic of schizophrenia. Furthermore, deficits in executive function and attention were found in schizophrenic patients with average premorbid intellectual levels and no evidence of IQ decline, indicating that these deficits may be core features of schizophrenia independent of the variability of IQ impairment among patients.

    Article  PubMed  CAS  Google Scholar 

  13. Rabinowitz J, Reichenberg A, Weiser M, et al.: Cognitive and behavioural functioning in men with schizophrenia both before and shortly after first admission to hospital: crosssectional analysis. Br J Psychiatry 2000, 177:26–32.

    Article  PubMed  CAS  Google Scholar 

  14. Fucetola R, Seidman LJ, Kremen WS, et al.: Age and neuropsychologic function in schizophrenia: a decline in executive abilities beyond that observed in healthy volunteers. Biol Psychiatry 2000, 48:137–146.

    Article  PubMed  CAS  Google Scholar 

  15. Granholm E, Morris S, Asarnow RF, et al.: Accelerated age-related decline in processing resources in schizophrenia: evidence from pupillary responses recorded during the span of apprehension task. J Int Neuropsychol Soc 2000, 6:30–43.

    Article  PubMed  CAS  Google Scholar 

  16. Eyler Zorrilla LT, Heaton RK, McAdams LA, et al.: Crosssectional study of older outpatients with schizophrenia and healthy comparison subjects: no differences in age-related cognitive decline. Am J Psychiatry 2000, 157:1324–1326.

    Article  Google Scholar 

  17. Heaton RK, Gladsjo JA, Palmer BW, et al.: Stability and course of neuropsychological deficits in schizophrenia. Arch Gen Psychiatry 2001, 58:24–32.

    Article  PubMed  CAS  Google Scholar 

  18. Green MF: What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 1996, 153:321–330.

    PubMed  CAS  Google Scholar 

  19. Green MF, Kern RS, Braff D, et al.: Neurocognition and functional outcome in schizophrenia: are we measuring the right stuff? Schizophr Bull 2000, 26:119–136.

    PubMed  CAS  Google Scholar 

  20. Addington J, Addington D: Neurocognitive and social functioning in schizophrenia: a 2.5 year follow-up study. Schizophr Res 2000, 44:47–56.

    Article  PubMed  CAS  Google Scholar 

  21. Velligan DI, Bow-Thomas CC, Mahurin RK, et al.: Do specific neurocognitive deficits predict specific domains of community function in schizophrenia? J Nerv Ment Dis 2000, 188:518–524. This work contributes to our understanding of which specific neurocognitive deficits predict community outcome. By understanding which neurocognitive functions determine specific domains of adaptive functioning compensatory strategies may be developed to improve community outcome. The results indicate that verbal memory predicts all measures of community outcome, vigilance predicts social outcome and executive functioning predicts work and activities of daily living.

    Article  PubMed  CAS  Google Scholar 

  22. McGurk SR, Moriarty PJ, Harvey PD, et al.: Relationship of cognitive functioning, adaptive life skills, and negative symptom severity in poor-outcome geriatric schizophrenia patients. J Neuropsychiatry Clin Neurosci 2000, 12:257–264.

    PubMed  CAS  Google Scholar 

  23. Schretlen D, Jayaram G, Maki P, et al.: Demographic, clinical, and neurocognitive correlates of everyday functional impairment in severe mental illness. J Abnorm Psychol 2000, 109:134–138.

    Article  PubMed  CAS  Google Scholar 

  24. Harvey PD, McGurk SR: Cost of schizophrenia: focus on vocational impairment. The Economics of Neuroscience 2000, 2:42–48.

    Google Scholar 

  25. Rupp A, Keith SJ: The cost of schizophrenia. Psychiatr Clin North Am 1993, 16:413–423.

    PubMed  CAS  Google Scholar 

  26. Sevy S, Davidson M: The cost of cognitive impairment in schizophrenia. Schizophr Res 1995, 17:1–3.

    Article  PubMed  CAS  Google Scholar 

  27. McGurk SR, Meltzer HY: The role of cognition in vocational functioning in schizophrenia. Schizophr Res 2000, 45:175–184.

    Article  PubMed  CAS  Google Scholar 

  28. Suslow T, Schonauer K, Ohrmann P, et al.: Prediction of work performance by clinical symptoms and cognitive skills in schizophrenic outpatients. J Nerv Ment Dis 2000, 188:116–118.

    Article  PubMed  CAS  Google Scholar 

  29. Medalia A, Dorn H, Watras-Gans S: Treating problem-solving deficits on an acute care psychiatric inpatient unit. Psychiatry Res 2000, 97:79–88.

    Article  PubMed  CAS  Google Scholar 

  30. Velligan DI, Bow-Thomas CC, Huntzinger C, et al.: Randomized controlled trial of the use of compensatory strategies to enhance adaptive functioning in outpatients with schizophrenia. Am J Psychiatry 2000, 157:1317–1323. This work provides new information on the effect of novel cognitive adaptation training techniques on the cognitive functions of schizophrenics. These compensatory strategies were found to significantly improve global functioning and psychotic symptoms and to significantly reduce relapse of schizophrenic patients rates over a 9-month follow-up.

    Article  PubMed  CAS  Google Scholar 

  31. Hegarty JD, Baldessarini RJ, Tohen M: One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am J Psychiatry 1994, 151:1409–1416.

    PubMed  CAS  Google Scholar 

  32. Davidson M, Keefe RSE: Cognitive impairment as a target for pharmacological treatment in schizophrenia. Schizophr Res 1995, 17:123–129.

    Article  PubMed  CAS  Google Scholar 

  33. Keefe RSE, Perkins S, Silva SM, et al.: The effect of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr Bull 1999, 25:201–222.

    PubMed  CAS  Google Scholar 

  34. Harvey PD, Keefe RSE: Studies of cognitive change with novel antipsychotic treatment in schizophrenia. Am J Psychiatry 2001, 158:176–184. This meta-analytic review of the treatment effects of atypical antipsychotic medications on the cognitive functions of schizophrenic patients highlights the methodological limitations in previous studies and therefore is helpful in the design of future studies. In addition, this review suggests that specific aspects of cognitive functioning are more improved than others by atypical antipsychotics. Finally, this review points out that the improvement in cognition with atypical antipsychotics is moderate at best.

    Article  PubMed  CAS  Google Scholar 

  35. Purdon SE, Jones BD, Stip E, et al.: Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol: the Canadian Collaborative Group for research in schizophrenia. Arch Gen Psychiatry 2000, 57:249–258. One of the first studies to directly compare the atypical antipsychotic medications on their cognitive effects in schizophrenic patients. While the results suggested some superior cognitive benefits of olanzapine relative to risperidone, this study was very limited by a small sample size and high rates of attrition.

    Article  PubMed  CAS  Google Scholar 

  36. Harvey PD, Moriarty PJ, Serper MR, et al.: Practice-related improvement in information processing with novel antipsychotic treatment. Schizophr Res 2000, 46:139–148.

    Article  PubMed  CAS  Google Scholar 

  37. Liu SK, Chen WJ, Chang CJ, et al.: Effects of atypical neuroleptics on sustained attention deficits in schizophrenia: A trial of risperidone versus haloperidol. Neuropsychopharmacology 2000, 22:311–319.

    Article  PubMed  CAS  Google Scholar 

  38. Allen DN, Goldstein G, Forman SD, et al.: Neurologic examination abnormalities in schizophrenia with and without a history of alcoholism. Neuropsychiatry Neuropsychol Behav Neurol 2000, 13:184–187. Despite the understanding that schizophrenic patients have a high rate of co-morbid substance abuse disorders, little is known about the adverse effects of these substances on neurologic and neuropsychological functions of schizophrenic patients. The results of this study suggest that schizophrenic patients with a history of alcoholism have greater overall neurologic impairment, particularly in the area of perceptual functions.

    PubMed  CAS  Google Scholar 

  39. Serper MR, Bergman A, Copersino ML: Learning and memory impairment in cocaine-dependent and comorbid schizophrenic patients. Psychiatry Res 2000, 93:21–32.

    Article  PubMed  CAS  Google Scholar 

  40. Serper MR, Copersino ML, Richarme D: Neurocognitive functioning in recently abstinent, cocaine-abusing schizophrenic patients. J Subst Abuse 2000, 11:205–213.

    Article  PubMed  CAS  Google Scholar 

  41. Brebion G, Amador X, David A, et al.: Positive symptomatology and source-monitoring failure in schizophrenia: an analysis of symptom-specific effects. Psychiatry Res 2000, 95:119–131.

    Article  PubMed  CAS  Google Scholar 

  42. Bocker KB, Hijman R, Kahn RS, et al.: Perception, mental imagery and reality discrimination in hallucinating and non-hallucinating schizophrenic patients. Br J Clin Psychol 2000, 39:397–406.

    Article  PubMed  Google Scholar 

  43. O’Leary DS, Flaum M, Kesler ML, et al.: Cognitive correlates of the negative, disorganized, and psychotic symptom dimensions of schizophrenia. J Neuropsychiatry Clin Neurosci 2000, 12:4–15. This study increases our knowledge of the relationship between specific cognitive abnormalities and clinical symptoms of schizophrenia. The results indicate that negative symptoms are related to impaired verbal learning and memory, verbal fluency and visual memory while disorganized symptoms are related to lower verbal IQ and poor concept attainment.

    PubMed  CAS  Google Scholar 

  44. Brebion G, Amador X, Smith M, et al.: Depression, psychomotor retardation, negative symptoms, and memory in schizophrenia. Neuropsychiatry Neuropsychol Behav Neurol 2000, 13:177–183.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry, Mount Sinai School of Medicine, Box 1229, 10029, New York, NY, USA

    Philip D. Harvey Phd, Christopher R. Bowie MA & Joseph I. Friedman MD

Authors
  1. Philip D. Harvey Phd
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christopher R. Bowie MA
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Joseph I. Friedman MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Harvey, P.D., Bowie, C.R. & Friedman, J.I. Cognition in schizophrenia. Curr Psychiatry Rep 3, 423–428 (2001). https://doi.org/10.1007/s11920-996-0038-7

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11920-996-0038-7

Keywords

Search

Navigation